Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Repatha (evolocumab by Year
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide volume growth YoY (%) (%)
Amgen Repatha (evolocumab: 43.0% in FY2024, up 6.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“Full year sales increased 36%, primarily driven by 43% volume growth, partially offset by 10% lower net selling price.”
Source: Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 43.0% | +6.0 pts | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 37.0% | -21.0 pts | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 58.0% | +23.0 pts | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 35.0% | -32.0 pts | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 67.0% | – | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
Cite this data
StockData. (2026). Amgen Repatha (evolocumab (%), annual FY2020–FY2024 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-repatha-vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.